Bifogade filer
Bokslutskommuniké Januari December 2021 ProstaLund AB ENG
Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från ProstaLund AB (publ) via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2022-02-18 08:08:00
Growth with almost 50 %* increase for our BPH treatment method, CoreTherm
1 January-31 December
- Net sales reached SEK 17.1 (12.5) million
- Loss after taxes SEK -7.9 (-10.0) million
- Earnings per share were SEK -0.17 (-0.27)
- Cash and equivalents were 13.2 (10.5) million
- The Board of Directors proposes that no dividend
will be paid for 2021
Significant events during period
- Agency agreement signed in Finland
- Three clinics are appointed Centre of Excellence
* in treatment catheters
| Key figures | |||||
| (SEK MILLION) | Jan-Dec 2021 | Jan-Dec 2020 | Jan-Dec 2019 | Jan-Dec 2018 | Jan-Dec 2017 |
| Net sales | 17.1 | 12.5 | 12.9 | 13.6 | 13.5 |
| Gross margin, % | 86 | 77 | 70 | 60 | 66 |
| Operating profit/loss | -7.9 | -9.9 | -10.4 | -13.0 | -16.9 |
| Cash flow from operating activities | -5.8 | -8.6 | -9.2 | -11.9 | -16.1 |
| Average number of employees | 7 | 6 | 5 | 8 | 11 |
1 October-31 December
- Net sales reached SEK 4.9 (3.7) million
- Loss after taxes SEK -2.2 (-3.7) million
- Earnings per share were SEK -0.04 (-0.09)
Significant events after the end of the period
- Distribution agreement signed for the UK market
- Utility patent was approved in China
” During the year, we have shown that our product portfolio and our treatment concept are to be counted on and I am convinced that we will see further success in 2022.”
Johan Wennerholm
CEO, ProstaLund AB (publ)
Please see attached appendix for full report.